Biohaven Reports Negative Data From Spinocerebellar Ataxia Phase 2/3 Trial

(RTTNews) - Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported topline results from its Phase 2/3 clinical trial evaluating trigriluzole compared to placebo for the treatment of patients with spinocerebellar ataxia. In the trial, trigriluzole did not differentiate from placebo on the primary endpoint of the mean change from baseline on the scale for the assessment and rating of Ataxia after eight weeks of treatment. Trigriluzole also did not differentiate on the key secondary efficacy endpoint of patient's global impression of change. However, trigriluzole did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events and low discontinuation rates due to adverse events.

The eight-week trial dosed 141 adult SCA patients at 18 centers in the United States.